The DOI matches its Crossref record.
Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis
Abstract
BACKGROUND: Despite the increasing prevalence of drug-resistant tuberculosis, most low- and middle-income countries use standardized regimens, without assessment of drug susceptibility. PURPOSE: To perform a systematic review and meta-analysis of the effect of initial drug resistance and treatment regimen on tuberculosis treatment outcomes. DATA SOURCES: PubMed, the Cochrane Central Database of Clinical Trials, and EMBASE were searched for studies published in English from 1965 to June 2007. Additional studies were identified from cited references. STUDY SELECTION: Randomized, controlled trials and cohort studies of standardized treatment of previously untreated patients with culture-confirmed pulmonary tuberculosis. Drug-susceptibility testing was done on pretreatment isolates from all patients and from patients with treatment failure or relapse. DATA EXTRACTION: Two authors reviewed the studies for methods, initial drug resistance, treatment regimens, and outcomes. DATA SYNTHESIS: Pooled cumulative incidences were computed with random-effects meta-analyses. Association between risk factors and outcomes were determined by using stratified analyses. The cumulative incidence of acquired drug resistance with initially pan-sensitive strains was 0.8% (95% CI, 0.5% to 1.0%) compared with 6% (CI, 4% to 8%) with initially single drug-resistant strains and 14% (CI, 9% to 20%) with initially polydrug-resistant strains. Failure and relapse were most strongly associated with initial drug resistance. Failure was also associated with shorter duration of rifampin therapy and nonuse of streptomycin, whereas the rate of relapse was higher with shorter duration of rifampin therapy and nonuse of pyrazinamide. LIMITATIONS: Few studies included HIV-infected persons, and treatment outcomes were pooled despite considerable heterogeneity. CONCLUSION: Treatment outcomes were substantially worse in the presence of initial drug resistance, which has important implications in resource-limited settings in which drug resistance is prevalent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Antibiotic resistance and its cost: is it possible to reverse resistance?
Andersson, D. I., & Hughes, D. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2319 · Cited by 2,294
Lewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw694 · Cited by 992
“Drug susceptibility testing is essential because treatment success for patients with MDR-TB (can reach 75% or higher [150, 151]) is dependent upon patients being treated with an effective antimicrobial regimen [152].”
BackgroundSelf-citationShort, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
National Survey of Drug-Resistant Tuberculosis in China
Zhao, Y., Xu, S., Wang, L., Chin, D. P., Wang, S., Jiang, G., Xia, H., Zhou, Y., Li, Q., Ou, X., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108789 · Cited by 631
Orenstein, E. W., Basu, S., Shah, N. S., Andrews, J. R., Friedland, G. H., Moll, A. P., Gandhi, N. R., & Galvani, A. P. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70041-6 · Cited by 540
Metadata
- Authors
- Lew, W., Pai, M., Oxlade, O., Martin, D., & Menzies, D.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2008-07-15
- Volume
- 149
- Issue
- 2
- Pages
- 123-134
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W1981511719
- Cited by
- 187
- References
- 0
- FWCI
- 1.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis. https://app.cochat.ai/papers/10.7326/0003-4819-149-2-200807150-00008
- The paper
- Lew, W., Pai, M., Oxlade, O., Martin, D., & Menzies, D. (2008). Initial Drug Resistance and Tuberculosis Treatment Outcomes: Systematic Review and Meta-analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-149-2-200807150-00008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.